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Antiphospholipid antibody syndrome (APS) may occur in a primary form or in association with SLE and seldom presents with
nephrotic syndrome (NS). We present a case with APS who developed recurrent NS 6 years apart. The first episode of NS occurred
with biopsy findings consistent with lupus nephritis (LN) class V (membranous) with no clear evidence of SLE, and responded to
a remission with steroids and MMF. On the 2nd episode, the biopsy revealed negative immunofluorescent (IF) study for immune
complexes and EM findings of complete effacement of foot processes and acellular debris in thickened capillary walls, compatible
with healed previous episode of membranous LN andminimal change disease (MCD), a nonimmune complex podocytopathy.The
2nd episode responded to a partial remission, primarily with a short-term steroid therapy, and subsequently developed serologic
evidence of SLE. Now there is growing evidence that a subset of SLE patients with NS are found to have MCD, likely due to
podocyte injury caused by nonimmune complex pathway, called lupus podocytopathy. In LN, serial kidney biopsies often show
transformation fromone to another class of immune complex-induced glomerular lesions; however there are rare reports describing
transformation of an immune complex to a nonimmune complex LN. Since the pathogenic mechanism of lupus podocytopathy
is not delineated, and so far there are no reports on transformation of membranous LN, an immune complex nephropathy, to
a nonimmune complex lupus podocytopathy, it still remains as a question whether our case with APS overlapping SLE had a
concomitant membranous LN and lupus podocytopathy, or consequential membranous LN and lupus podocytopathy 6 years
apart.
1. Introduction
We present a case with antiphospholipid antibody syndrome
(APS) who developed recurrent nephrotic syndrome (NS) 6
years apart. The first episode occurred with biopsy findings
consistent with lupus nephritis (LN) class V (membranous)
without clinical evidences of systemic lupus erythematosus
(SLE), and the second episode occurred with pathologic
findings of a nonimmune complex podocytopathy on the
repeat kidney biopsy, subsequently with positive serologic
evidences of SLE.
2. Case Presentation
AnAfricanAmericanmanwith the diagnosis of APS at age 18
was admitted with thrombosis of inferior vena cava and left
renal vein, and found to have NS (16 g of protein in 24 h urine
and serum albumin 1.7 g/dL) at age 25. The kidney biopsy
revealed findings consistent with lupus nephritis (LN) class V
(membranous). He had a brief episode of thrombocytopenia
and prolonged PTT and negative serology for SLE except one
positive ANA. He was treated with prednisone (up to 40 mg
p.o. daily), mycophenolate mofetil (MMF) up to 1.5 g p.o.
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Figure 1: Thickened mesangium and capillary loops PAS 200x.
bid, enalapril, simvastatin, and warfarin. The follow-up visit
in 4 months revealed serum creatinine (Scr) 1.2 mg/dL (0.11
mmol/L), serum albumin (Salb) 3.4 g/dL, and 0.6 g protein
in 24 h urine. Six years later, at age 31, he presented with
recurrent NS (11.5 g of protein in 24 h urine and Salb 2.2
g/dL), and without any recent allergic reaction or exposure to
NSAIDs. Physical exam revealed BP 130/85 mmHg, weight
121.8 kg, height 198 cm, no abnormal skin lesions, but 2+
pitting edema of both lower legs; otherwise there were no
remarkable findings. Lab studies showed Hgb of 12.3 g/dL,
Hct 36.4%, WBC 6,600 /𝜇L and platelet 154,000 /𝜇L, urine
microscopic exam with RBC 21-50/HPF, BUN 24 mg/dL (4
mmol/L), Scr 1.1 mg/dL (0.1 mmol/L), negative SLE serology
(ANA, anti-dsDNA, anti-Smith, cardiolipin antibody), C
3
84
(N:85-288), C
4
24 (N:17-64), CH
50
45 (N: 31-60), and positive
beta-2 glycoprotein 1 (IgA). Under the impression of recur-
rent membranous LN, he was placed on methylprednisolone
(48 mg p.o. daily) and MMF (1.5 g p.o. bid) and enalapril (10
mg p.o. daily) and then developed disseminated herpes zoster
(HZ) in 4 weeks. MMF was stopped and he was started on
IV acyclovir and continued on methylprednisolone (Medrol)
24 mg p.o. daily. Upon resolution of HZ, a second biopsy
was performed with findings of thickened capillary walls
with lucencies, moderate mesangial matrix expansion, and
no podocytes abnormality on the light microscopy (LM)
(Figure 1), and negative immunofluorescent study (IF) for
IgG, IgA, C3, C1q, light chains, and faint IgM on IF, and
electronmicroscopy (EM) with complete (90-100%) efface-
ment of foot processes, acellular debris in thickened capillary
walls, and sparse immune deposits in mesangium (Figure 2),
whichwere consistent with healedmembranous nephropathy
(MN) and minimal change disease- (MCD-) like process.
After his discharge from the hospital on Medrol 24 mg daily,
enalapril, warfarin, and intermittent use of furosemide, he did
not come for follow-up, stating “no more swelling of legs”
and “I am feeling fine.” Four months after discharge (not on
Medrol for 3 months), he came for lab tests, which showed
Scr 1.37 mg/dL (1.21 mmol/L), Salb 3.0 g/dL, 3.2 g of protein
in 24 h urine, positive ANA (1:80), and positive anti-ds
DNA.
Figure 2: Thickened capillary walls with acellular debris, total foot
process effacement on EM.
3. Discussion
It is known that APS, an autoimmune disease, may occur
as a primary form without any underlying disease or in
association with SLE [1], and that 37% of patients with SLE
have positive beta-2-glycoprotein 1 antibodies [2]. In the pri-
mary APS, features of thrombotic microangiopathy (TMA)
are the most characteristic lesions of APS nephropathy [3];
nephrotic syndrome (NS) is rare, but described with presence
of thrombosis of renal vein [4].
In our case with the diagnosis of APS at age 18, the
first episode of NS at age 25 was found with biopsy findings
consistent of membranous lupus nephropathy (LN Class V)
and his NS responded to remission with steroid and MMF
therapy. At age 31 (six years later), the second episode of NS
occurred, and the second kidney biopsy revealed negative IF
for IgG, IgA, C3, and C1q, except faint IgM, with EM findings
of complete effacement of foot processes and acellular debris
in thickened capillary walls compatible with the diagnosis of
a nonimmune complex podocytopathy and healed previous
episode of membranous LN. The second episode of NS with
minimal change disease/lupus podocytopathy responded to
partial remission, primarily to a short-term steroid therapy.
A subset of SLE patients with NS have been found to have
no evidence of immune complex deposition or endocapillary
proliferation/inflammation on kidney biopsy, comparable
to minimal change disease (MCD), and due to podocyte
injury caused by nonimmune complex pathway called lupus
podocytopathy [5, 6].
Rare case reports of MCD in SLE started to appear in
Japanese literature (1984) and English literature (1995) [5].
In 2002, Dube et al. [5] reported the clinical and pathologic
findings in 7 patients with SLE and MCD, and highlighted
the entity as an underrecognized and highly reversible form
of NS in patients with SLE. In 2005, Kraft et al. [6] reported
the development of nephrotic range proteinuria in 8 SLE
patients with no evidence of peripheral capillary immune
complex deposition and called it glomerular podocytopathy.
In 2016,Hu et al. [7] reported 50 cases of lupus podocytopathy
(minimal change in 13 cases, mesangial proliferation in 28
cases, and FSGS in 9 cases) from 3,750 biopsies of SLE
patients, and described different responses to treatment
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and its outcomes, in parallel with the underlying histologic
patterns.
The pathogenic mechanism of MCD/lupus podocytopa-
thy is not well delineated, even though abnormal T-cell medi-
ated immune responses have been implicated in idiopathic
MCD [8].
Now there is growing evidence for glomerular podocytes
as immunologically active cells. Podocytes can have upreg-
ulated B7-1 molecule involved in T-cell costimulation by
lipopolysaccharide (LPS) via TLR4 and lead to proteinuria
by altering slit diaphragm [9], and podocytes also act as
antigen presenting cells, participating in immune-mediated
glomerular diseases [10].
In our case, the first episode of nephrotic syndrome
occurred with membranous LN (Class V), an immune
complex nephropathy; then a second episode occurred six
years later with lupus podocytopathy, a nonimmune complex
nephropathy. In LN, serial kidney biopsies often show trans-
formation from one to another class of immune complex-
induced glomerular lesions. There is also one case report
[11] describing a 45-year-old lady with LN Class III (focal
proliferative) who developed NS 5 years later, and had his-
tologic changes consistent with MCD on the repeat biopsy. It
could mean that lupus podocytopathy may occur in a healed
late stage of an immune complex-induced lupus nephritis.
However, so far no reports of transforming membranous LN,
immune complex nephropathy, to a nonimmune complex
lupus podocytopathy are found in English literature. It is
reported that relapse or worsening of NS in idiopathic mem-
branous nephropathy can occur even though the glomerular
immune deposits have been eradicated [12], and nephrotic
range proteinuria in patientswithmembranous LNwas better
correlated with the degree of foot process effacement than
the degree of immune complex deposition, pointing to it as
manifestation of concomitant podocyte dysfunction [13].
4. Conclusion
Since the pathogenic mechanism of lupus podocytopathy
is not delineated, and so far there are no reports on
transformation of membranous LN, an immune complex
nephropathy, to a nonimmune complex lupus podocytopa-
thy, it still remains as a question whether our case with APS
overlapping SLE had a concomitant membranous LN and
lupus podocytopathy, or consequential membranous LN and
lupus podocytopathy 6 years apart.
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